Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Revenue (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Revenue for 16 consecutive years, with $23.7 million as the latest value for Q4 2025.

  • Quarterly Revenue fell 3.34% to $23.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.6 million through Dec 2025, down 8.06% year-over-year, with the annual reading at $86.6 million for FY2025, 8.06% down from the prior year.
  • Revenue for Q4 2025 was $23.7 million at Harvard Bioscience, up from $20.6 million in the prior quarter.
  • The five-year high for Revenue was $33.1 million in Q4 2021, with the low at $20.4 million in Q2 2025.
  • Average Revenue over 5 years is $26.3 million, with a median of $27.0 million recorded in 2021.
  • The sharpest move saw Revenue increased 25.27% in 2021, then decreased 19.69% in 2024.
  • Over 5 years, Revenue stood at $33.1 million in 2021, then fell by 14.0% to $28.4 million in 2022, then dropped by 0.96% to $28.2 million in 2023, then dropped by 12.78% to $24.6 million in 2024, then dropped by 3.34% to $23.7 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $23.7 million, $20.6 million, and $20.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.